Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

por Moraes, Carolina B., Giardini, Miriam A., Kim, Hwayoung, Franco, Caio H., Araujo-Junior, Adalberto M., Schenkman, Sergio, Chatelain, Eric, Freitas-Junior, Lucio H.
Publicado 2014

In Vitro Anti-Trypanosoma cruzi Activity of Halophytes from Southern Portugal Reloaded: A Special Focus on Sea Fennel (Crithmum maritimum L.)

por Pereira, Catarina G., Moraes, Carolina Borsoi, Franco, Caio H., Feltrin, Clarissa, Grougnet, Raphaël, Barbosa, Euzébio Guimarães, Panciera, Michele, Correia, Carlos Roque D., Rodrigues, Maria João, Custódio, Luísa
Publicado 2021

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity

por Franco, Caio H., Warhurst, David C., Bhattacharyya, Tapan, Au, Ho Y.A., Le, Hai, Giardini, Miriam A., Pascoalino, Bruno S., Torrecilhas, Ana Claudia, Romera, Lavinia M.D., Madeira, Rafael Pedro, Schenkman, Sergio, Freitas-Junior, Lucio H., Chatelain, Eric, Miles, Michael A., Moraes, Carolina B.
Publicado 2020